Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Ou H, Huang Z, Mo Z, Xiao Ji, Humana Press Inc (2017) The characteristics and roles of advanced oxidation protein products in atherosclerosis
Lancet 403 , 10271050 (2024)
Lipid-lowering medications that inhibit the activity of 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase (statins), a critical enzyme in both cholesterol and coenzyme Q 10 biosynthesis, decrease plasma coenzyme Q 10 concentrations (see HMG-CoA reductase inhibitors [statins]), although it remains unproven that this has any clinical implications
doi:10.2337/dc24-SINT Davies MJ, et al
If a psychiatric tool can produce that outcome by acting on those circuits, GLP-1 agonists which act on the same circuits continuously belong in the psychiatric toolbox
Supporting the full network may deliver meaningfully better results
